6360abefb0d6371309cc9857
Abstract
Fibrodysplasia Ossificans Progressiva (FOP), also
known as stoneman syndrome, is a rare autosomal dominant genetic disorder
characterized by abnormal bone development in non-skeletal areas, causing
significant suffering. Due to its rarity, awareness and understanding are
lacking, leading to delayed diagnoses. This article aims to raise awareness for
early detection and treatment, sparking further research.
Keywords: Fibrodysplasia; Ossificans; Progressiva; Stone man; Genetic
Short review
Fibrodysplasia Ossificans Progressiva (FOP) or stoneman
syndrome is a rare autosomal dominant genetic disorder characterised by the
abnormal development of bone in areas of the body where bone is not normally
present, hence causing a lot of misery for those affected. Due to its rarity,
there is a lack of awareness and knowledge on this disease, leading to a faulty
or late diagnosis. Very little is understood about the disease, which can make
it challenging to effectively administer analgesia to FOP patients. This
article is aimed at spreading awareness of this disease, to ensure an early
diagnosis and provide necessary treatment to minimise suffering for those
affected and possibly ignite further research into its mechanism and treatment.
Aside from being inherited, FOP can be caused by a mutation
in gene 2q23-24 which encodes a bone morphogenetic protein receptor called
Activin Receptor Type IA (ACVR1)1. The presence of bone morphogenetic protein
(BMP) receptors on the surface of cells plays a role in deciding the fate of
the stem cells. More specifically, FOP results in the specific substitution of
arginine, at position 206 in the ACVR1 protein for histidine. A mutation in
such an important receptor changes the fate of stem cells, for example, the
cells which were supposed to develop into and grow as soft tissue, may end up
ossifying and becoming osseous tissue, which is the characteristic trait of
FOP.
The first signs of FOP are congenital deformations in the
toes. Heterotopic ossification initially begins with firm and tender swellings
on specific body parts such as the back, neck, and shoulders. These swellings
cause pain and stiffness and eventually turn into mature bone as they shrink.
While this abnormal bone growth can happen without any specific cause, it often
occurs after a soft tissue injury or a viral illness2.
Furthermore, Swelling may occur due to obstruction of tissue fluid by
abnormal bone formation. Affected joints may have severely restricted motion
causing immobilisation, causing them to require a wheelchair by their late 20s.
The individual may also have kyphosis or scoliosis and may exhibit an increased
susceptibility to respiratory infection or right sided congestive heart
failure. Some cases have even shown hearing impairment, hair loss and mild
cognitive delay3. Those with FOP have three times higher
probability of developing renal stones than the general population. Nausea,
swallowing difficulty, vomiting, gastroesophageal reflux, etc further reduce
their quality of life4.
There isn’t yet a permanent cure but courses of high-dose
corticosteroids at the start of a flare-up can reduce some of the symptoms of
the condition. Affected persons may participate in occupational therapy and
palliative care can be administered. They must avoid any physical trauma and
must take measures to avoid viral illnesses to prevent the symptoms from
spreading or worsening. Furthermore, subcutaneous injections should be
preferred over intramuscular injections.
This disease affects roughly one in two million people and
can become severely disabling. People with FOP have a median lifespan of 40
years. There are around 900 known patients out of an estimated 4000 affected
individuals globally. This disorder affects both males and females from all
ethnic backgrounds5.
Due to its low prevalence, there is a dearth of knowledge
about the disease as well as the paucity of information available about its
treatment. FOP is an illness that causes a great deal of distress for people,
the different symptoms linked with the ailment decrease quality of life, making
it even worse and necessitating substantial studies to learn more about this
health issue. Hence, there is a dire need to work on the development of
effective treatments for fibrodysplasia ossificans progressiva.
Conflicts of interest
This
study does not have any conflict of interest.
References
2. Kaplan FS, Al Mukaddam M, Pignolo RJ. Longitudinal patient reported mobility assessment
in fibrodysplasia ossificans progressiva (FOP). Bone 2018;109:158-161.
3. Morales-Piga A,
Bachiller-Corral J,
Trujillo-Tiebas MJ, et al. Fibrodysplasia ossificans progressiva in Spain:
epidemiological, clinical, and genetic aspects. Bone 2012;51(4):748-755.
4. Kannu P, Levy CE. Improving the diagnosis of
fibrodysplasia ossificans progressiva. J Pediatr 2021;232:3-8.
5. Pignolo RJ, Hsiao EC, Baujat
G, et al. Prevalence of
fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from
three treatment centers and a patient organization. Orphanet J Rare Dis
2021;16(1):1-8.